MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from offerings,
net of issuance...
$46,704K
Proceeds from issuance of
stock pursuant to...
$2,961K
Stock-based compensation
expense
$32,162K
Depreciation and
amortization expense
$25,224K
Exercise of stock options
$2,022K
Accounts payable and
accrued expenses
$12,100K
Other assets and
liabilities
-$11,970K
Legal reserves
-$5,560K
Other
$3,163K
Change in third party
payor reserves
-$2,449K
Change in fair value of
financial liabilities
$1,204K
Provision for excess and
obsolete inventory
$135K
Net cash provided by
financing activities
$48,025K
Net cash provided by
(used in) operating...
$33,279K
Canceled cashflow
$3,662K
Canceled cashflow
$60,688K
Net increase
(decrease) in cash, cash...
$19,787K
Canceled cashflow
$61,517K
Finance lease payoff and
principal payments
$2,451K
Long-term debt principal
payments
$1,211K
Proceeds from maturities
of marketable...
$43,970K
Proceeds from sales of
marketable securities
$2,062K
Accounts receivable
$36,231K
Net loss
-$21,021K
Inventory
$3,436K
Net cash used in
investing activities
-$61,517K
Canceled cashflow
$46,032K
Purchases of marketable
securities
$55,676K
Acquisition of business, net
of cash acquired...
$32,856K
Purchases of property and
equipment
$19,017K
Back
Back
Cash Flow
source: myfinsight.com
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)